Retraction: Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing hif-1-dependent expression of vegf (PLOS ONE (2012) 7:8 (e42913) DOI: 10.1371/journal.pone.0042913);Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Medici, Damian ^a,b   Olsen, Bjorn R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; SMALL INTERFERING RNA; VASCULOTROPIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HEMANGIOMA; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84865029396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0234141     Document Type: Erratum

References (22)

1. Boye E, Yu Y, Paranya G, Mulliken JB, Olsen BR, et al. ((2001)) Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 107:: 745--752.
2. Jinnin M, Medici D, Park L, Limaye N, Liu Y, et al. ((2008)) Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 14:: 1236--1246.
3. Clauss M, ((1998)) Functions of the VEGF receptor-1 (FLT-1) in the vasculature. Trends Cardiovasc Med 8:: 241--245.
4. Semenza GL, ((2000)) HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88:: 1474--1480.
5. Manalo DJ, Rowan A, Lavole T, Natarajan L, Kelly BD, et al. ((2005)) Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105:: 659--669.
6. Ke Q, Costa M, ((2006)) Hypoxia-Inducible Factor-1 (HIF-1). Mol Phamacol 70:: 1469--1480.
7. Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW, ((2004)) Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 36:: 1--12.
8. Garcia-Meceira P, Mateo J, ((2009)) Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 28:: 313--324.
9. Bian CX, Shi Z, Meng Q, Jiang Y, Liu LZ, et al. ((2010)) P70S6K1 regulation of angiogenesis through VEGF and HIF-1alpha expression. Biochem Biophys Res Commun 398:: 395--399.
10. Vignot S, Faivre S, Aguirre D, Raymond E, ((2005)) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:: 525--537.
11. Cantley LC, ((2002)) The phosphoinositide 3-kinase pathway. Science 296:: 1655--1657.
12. Wong KK, Engelman JA, Cantley LC, ((2010)) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20:: 87--90.
13. Tee AR, Blenis J, ((2005)) mTOR, translational control and human disease. Semin Cell Dev Biol 16:: 29--37.
14. Ballou LM, Lin RZ, ((2008)) Rapamycin and mTOR kinase inhibitors. J Chem Biol 1:: 27--36.
15. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. ((1996)) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:: 4604--4613.
16. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, et al. ((2004)) Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven autocrine loop necessary for tumorigenesis. Cancer Cell 6:: 485--495.
17. Kleinmann ME, Greives MR, Churgin SS, Blechman KM, Chang EI, et al. ((2007)) Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in childrem with hemangioma. Arterioscler Thromb Vasc Biol 27:: 2664--2670.
18. Straatman L, Coles J, ((2000)) Pediatric utilization of rapamycin for severe cardiac allograft rejection. Transplantation 70:: 541--543.
19. Oellerich M, Armstrong VW, Streit F, Weber L, Tonshoff B, ((2004)) Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin Biochem 37:: 424--428.
20. Koenig MK, Northrup H (2009) Topical rapamycin therapy to alleviate cutaneous manifestations of tuberous sclerosis complex (TSC) and neurofibromatosis (NF1). ClinicalTrials.gov NCT01031901.
21. Hamilton HK, Tonkovic-Capin V, ((2011)) Images in clinical medicine. Facial angiofibromas associated with tuberous sclerosis. 364:: 1061.
22. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, et al. ((2010)) Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 16:: 1400--1406.